Neurogastrx raises $45M series A

Gastrointestinal company Neurogastrx Inc. (Boston, Mass.) raised $45 million on Jan. 4 in a tranched series A round co-led by new investors 5AM Ventures, OrbiMed Advisors and venBio. The GI company also hired Jim O'Mara as CEO and appointed OrbiMed’s Klaus Veitinger as chairman.

O'Mara, who was SVP of corporate development at Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), told BioCentury that Neurogastrx expects to submit an IND in 1Q19 for lead candidate NG101 to treat gastroparesis. NG101 is a dopamine D2 and D3 receptor (DRD3) antagonist...